Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.
Adolescent
Adult
Anti-Bacterial Agents
/ pharmacology
Child
Child, Preschool
Drug Resistance, Multiple, Bacterial
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Pakistan
/ epidemiology
Salmonella typhi
/ drug effects
Travel-Related Illness
Typhoid Fever
/ drug therapy
United States
/ epidemiology
Young Adult
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
11 Jan 2019
11 Jan 2019
Historique:
entrez:
11
1
2019
pubmed:
11
1
2019
medline:
12
1
2019
Statut:
epublish
Résumé
In February 2018, a typhoid fever outbreak caused by Salmonella enterica serotype Typhi (Typhi), resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins, was reported in Pakistan. During November 2016-September 2017, 339 cases of this extensively drug-resistant (XDR) Typhi strain were reported in Pakistan, mostly in Karachi and Hyderabad; one travel-associated case was also reported from the United Kingdom (1). More cases have been detected in Karachi and Hyderabad as surveillance efforts have been strengthened, with recent reports increasing the number of cases to 5,372 (2). In the United States, in response to the reports from Pakistan, enhanced surveillance identified 29 patients with typhoid fever who had traveled to or from Pakistan during 2016-2018, including five with XDR Typhi. Travelers to areas with endemic disease, such as South Asia, should be vaccinated against typhoid fever before traveling and follow safe food and water practices. Clinicians should be aware that most typhoid fever infections in the United States are fluoroquinolone nonsusceptible and that the XDR Typhi outbreak strain associated with travel to Pakistan is only susceptible to azithromycin and carbapenems.
Identifiants
pubmed: 30629573
doi: 10.15585/mmwr.mm6801a3
pmc: PMC6342547
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-13Déclaration de conflit d'intérêts
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Références
Lancet Glob Health. 2014 Oct;2(10):e570-80
pubmed: 25304633
Clin Microbiol Rev. 2015 Oct;28(4):901-37
pubmed: 26180063
Clin Infect Dis. 2016 Aug 1;63(3):322-9
pubmed: 27090993
MBio. 2018 Feb 20;9(1):
pubmed: 29463654